SEARCH

SEARCH BY CITATION

References

  • 1
    Chitturi S, Farrell GC, Hashimoto E et al. Non-alcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 2007; 22:77887.
  • 2
    Chiturri S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia–Pacific region: future shock? J. Gastroenterol. Hepatol. 2004; 19: 36874.
  • 3
    Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 74550.
  • 4
    Sanyal AJ. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 2002; 123: 170525.
  • 5
    Bravo AA, Sheth SG, Chopra S. Current concepts: liver biopsy. N. Engl. J. Med. 2001; 344: 495500.
  • 6
    Van Der Poorten D, Kwok A, Lam T et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Int. Med. J. 2006; 36: 6929.
  • 7
    Wong VWS, Hui AY, Tsang SWC et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 115461.
  • 8
    Omagari K, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1098105.
  • 9
    Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 128692.
  • 10
    Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 110.
  • 11
    Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 2001; 21: 1726.
  • 12
    McCullough AJ. The epidemiology and risk factors of NASH. In: FarrellGC, HallPM, GeorgeJ, McCulloughAJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell, 2005; 2337.
  • 13
    Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am. J. Gastroenterol. 2004; 99: 7681.
    Direct Link:
  • 14
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 141319.
  • 15
    Hui AY, Wong VWS, Chan HLY et al. Histological progression of nonalcoholic fatty liver disease in Chinese patients. Aliment. Pharmacol. Ther. 2005; 21: 40713.
  • 16
    Brunt EM. Nonalcoholic steatohepatitis. Semin. Liver Dis. 2004; 24: 320.
  • 17
    Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers: associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 165060.
  • 18
    El Serag HB, Tran B, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 46068.
  • 19
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 135662.
  • 20
    Suzuki A, Angulo P, Lymp J et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005; 25: 77986.
  • 21
    Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH. TNF-alpha or adiponectin? Hepatology 2004; 40: 4654.
  • 22
    Poynard T, Ratziu V, Naveau S et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol. 2005; 4: 10.
  • 23
    Ratziu V, Massard J, Charlotte F et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease [Abstract]. BMC Gastroenterol. 2006; 6: 6.
  • 24
    Sebastiani G, Alberti A. Non-invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol. 2006; 12: 368294.
  • 25
    Fan JG, Saibara T, Chitturi S et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia–Pacific? J. Gastroenterol. Hepatol. 2007; 22: 794800.
  • 26
    Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 7228.
  • 27
    Petersen KF, Dufour S, Feng J et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. USA 2006; 103: 18277.
  • 28
    Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366: 105962.
  • 29
    Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 30
    Wong VWS, Hui AY, Tsang SWC et al. Prevalence of undiagnosed diabetes and post-challenge hyperglycemia in Chinese patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 121522.
  • 31
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 15763.
  • 32
    Tan CE, Chew SK, Ma S, Tai ES, Wai D. Can we apply the National Cholesterol Education Program Adult Treatment Panel Definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27: 11826.
  • 33
    Misra AM, Wasir JS, Pandey RM. An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diabetes Care 2005; 28: 398403.
  • 34
    Fan JG, Zhu J, Li XJ et al. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 2005; 20: 182532.
  • 35
    Oh JY, Sung YA, Hong YAS, Barrett-Connor E. Prevalence of the metabolic syndrome among Korean adults according to the criteria of the International Diabetes Federation. Diabetes Care 2006; 29: 9334.
  • 36
    Park HS, Han JH, Lee SY, Kim DJ, Kim SE. Prevalence of the metabolic syndrome among Korean adults according to the criteria of the International Diabetes Federation. Diabetes Care 2006; 29: 9334.
  • 37
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 3569.
  • 38
    Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005; 22: 11415.
  • 39
    Chen CH, Huang MH, Yang JC et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in non-obese adults. J. Clin. Gastroenterol. 2006; 40: 74552.
  • 40
    Wang RT, Koretz RL, Yee HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am. J. Med. 2003; 115: 5549.
  • 41
    Solga S, Alkhuraishe AR, Clark JM et al. Dietary composition and nonalcoholic fatty liver disease. Dig. Dis. Sci. 2004; 49: 157883.
  • 42
    Capristo E, Miele L, Forgione A et al. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur. Rev. Med. Pharmacol. Sci. 2005; 9: 2658.
  • 43
    Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 2005; 100: 107281.
    Direct Link:
  • 44
    Thomas EL, Brynes AE, Hamilton G et al. Effect of counseling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J. Gastroenterol. 2006; 12: 581319.
  • 45
    Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J. Gastroenterol. 2006; 12: 34553.
  • 46
    Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructans on glucose and lipid metabolism in patients with non-alcoholic steatohepatitis: results of a pilot study. Eur. J. Clin. Nutr. 2005; 59: 7236.
  • 47
    Hernandez R, Martinez-Lara E, Canuelo A et al. Steatosis recovery after treatment with a balanced sunflower or olive oil-based diet: involvement of perisinusoidal stellate cells. World J. Gastroenterol. 2005; 11: 748085.
  • 48
    Lanza-Jacoby S, Smythe C, Phetteplace H, Tabares A. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. J. Parenter. Enteral Nutr. 1992; 16: 3538.
  • 49
    Lai HS, Lin WH, Chen PR, Wu HC, Lee PH, Chen WJ. Effects of high-fiber diet on hepatocyte apoptosis and liver regeneration after partial hepatectomy in rats with fatty liver. J. Parenter. Enteral Nutr. 2005; 29: 4017.
  • 50
    Ackerman Z, Oron-Herman M, Grosovski M et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005; 45: 101218.
  • 51
    Lavoie JM, Yasari S, Bdennadher M, Paquette A. Effects of alternations (10 days) of high-fat with normal diet on liver lipid infiltration, fat gain and plasma metabolic profile in rats. Physiol. Behav. 2005; 86: 4428.
  • 52
    Gauthier MS, Favier R, Lavoie JM. Time course of the development of non-alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats. Br. J. Nutr. 2006; 95: 27381.
  • 53
    Stewart KJ, Bacher AC, Turner K et al. Exercise and risk factors associated with metabolic syndrome in older adults. Am. J. Prev. Med. 2005; 28: 918.
  • 54
    Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2006; 40 (3 Suppl. 1):S3943.
  • 55
    Cinar K, Coban S, Idilman R et al. Long-term prognosis of non-alcoholic fatty liver disease: is pharmacological therapy actually necessary? J. Gastroenterol. Hepatol. 2006; 21 (1 Pt 1): 16973.
  • 56
    De Hewavisenthi SJ, Dassanayake AS, De Silva HJ. Clinical, biochemical and histological characteristics of a Sri Lankan population of non-alcoholic steatohepatitis (NASH) patients. Ceylon Med. J. 2005; 50: 1336.
  • 57
    Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 41319.
  • 58
    Nobili V, Marcellini M, Devito R et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44: 45865.
  • 59
    Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997; 27: 1037.
  • 60
    Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 41319.
  • 61
    Suzuki A, Lindor K, St Saver J et al. Effect of changes on body weight and lifestyle in non-alcoholic fatty liver disease. J. Hepatol. 2005; 43: 106066.
  • 62
    Church TS, Kuk JL, Ross R, Priest EL, Biltoff E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 202330.
  • 63
    Sreenivasa Baba C, Alexander G, Kalyani B et al. Effects of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21: 1918.
  • 64
    Gauthier MS, Couturier K, Latour JG, Lavoie JM. Concurrent exercise prevents high-fat-diet–induced macrovesicular hepatic steatosis. J. Appl. Physiol. 2003; 94: 212734.
  • 65
    Gauthier MS, Couturier K, Charbonneau A, Lavoie JM. Effects of introducing physical training in the course of a 16-week high-fat diet regimen on hepatic steatosis, adipose tissue fat accumulation, and plasma lipid profile. Int. J. Obes. Relat. Metab. Disord. 2004; 28: 106471.
  • 66
    Terao T, Fujise T, Uchiyama S, Yamashita Y, Nakano S. Effects of swimming at two different water temperatures on hepatic lipid and lipoprotein levels in experimental fatty liver rats. Tokai J. Exp. Clin. Med. 1989; 14: 13945.
  • 67
    Osland EJ, Powell EE, Banks M, Jonsson JR, Hickman IJ. Obesity management in liver clinics: translation of research into clinical practice. J. Gastroenterol. Hepatol. 2007; 22: 5049.
  • 68
    St George A, Johnson A, Bauman A et al. Lifestyle intervention in early liver disease: metabolic changes at 3 months. J. Gastroenterol. Hepatol. 2006; 21 (Suppl. 4): A315.
  • 69
    Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54:6038.
  • 70
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 8934.
  • 71
    Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig. Liver Dis. 2004; 36: 40611.
  • 72
    Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2005; 21: 8719.
  • 73
    Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 2004; 20: 238.
  • 74
    Bugianesi E, Gentilcore F, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005; 100: 108290.
    Direct Link:
  • 75
    Loomba R, Lutrchman G, Kleiner D et al. Pilot study of metformin in patients with nonalcoholic steatohepatitis [Abstract]. Hepatology 2006; 44 (Suppl. 1): 260A.
  • 76
    Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 2004; 39: 18896.
  • 77
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma rosiglitazone. Hepatology 2003; 38: 100817.
  • 78
    Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 136470.
  • 79
    Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin. Gastroenterol. Hepatol. 2003; 1: 38443.
  • 80
    Sanyal AJ, Mofrad PS, Contos MJ et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2004; 2: 110715.
  • 81
    Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006; 355: 2297307.
  • 82
    McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis—promising but not ready for prime time. N. Engl. J. Med. 2006; 355: 23613.
  • 83
    Ratziu V, Charlotte F, Jacqueminet S et al. A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial [Abstract]. Hepatology 2006; 44 (Suppl. 1): 201A.
  • 84
    Satapathy SK, Garg S, Chauhan R et al. Beneficial effect of tumor necrosis factor inhibition by pentoxifylline on clinical, biochemical and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99: 194652.
    Direct Link:
  • 85
    Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99: 23658.
    Direct Link:
  • 86
    Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, promising new agent for patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001; 96: 271117.
    Direct Link:
  • 87
    Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad. Med. J. 2006; 82: 31522.
  • 88
    Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized tiral. Hepatology 2004; 39: 77078.
  • 89
    Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for treatment of nonalcoholic steatohepatitis: results of a randomized placebo controlled study [Abstract]. Hepatology 2006; 44 (Suppl. 12): 200A.
  • 90
    Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 69095.
  • 91
    Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J. Clin. Gastroenterol. 2006; 40 (3 Suppl. 1): S4450.
  • 92
    Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 164754.
  • 93
    Kral JG, Thung SN, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135: 4858.
  • 94
    Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord. 1998; 22: 2226.
  • 95
    Silverman EM, Sapala JA, Appelman HD. Regressionof hepatic steatossi in morbidly obese persons after gastric bypass. Am. J. Clin. Pathol. 1995; 104: 2331.
  • 96
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (2 Suppl. 1): S99112.
  • 97
    Bouldin MJ, Ross LA, Sumrall CD, Loustalot FV, Low AK, Land KK. The effect of obesity surgery on obesity. Am. J. Med. Sci. 2006; 331: 18393.
  • 98
    Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol. 1991; 12: 249.
  • 99
    American Diabetes Association. Standards of medical care in diabetes—2006. Diabetes Care 2006; 29: S442.